Renuology Is Building the Infrastructure Behind Personalized Peptide Care

The Peptide Boom Has a Clinical Infrastructure Problem

Peptide medicine is moving into the mainstream, but the systems supporting it have not kept pace. Many medical practices are interested in offering more personalized longevity care, yet face a fragmented landscape of suppliers, dosing resources, scientific literature, and training. Renuology believes the next stage of the industry will not be defined by access to peptides alone, but by the clinical infrastructure surrounding them.

At the center of that effort is Ashlee Kaufman, PA C, MMS, CEO and Co Founder of Renuology. With nearly three decades of experience across clinical medicine, product development, entrepreneurship, and health and wellness, Kaufman is building a company around a question that challenges conventional approaches to wellness: What does the individual patient actually need?

Renuology's work combines personalized testing, medical grade peptide access, practitioner education, and its PeptideRx.Health platform. Together, these initiatives reflect the company's ambition to help medical practices move beyond one size fits all longevity care and toward a more informed, practitioner led approach.

“I believe the biggest evolution in wellness isn't another product. It's understanding the person before choosing the product,” Kaufman says.

From One Size Fits All To Individualized Care

The growing interest in peptides has created new opportunities for healthcare practices exploring longevity medicine. It has also introduced practical questions about education, sourcing, protocol organization, and clinical implementation.

For practices, the challenge is not simply deciding whether peptides belong in their services. It is understanding how to evaluate information, organize protocols, educate clinicians, and maintain appropriate medical oversight.

Renuology sees this gap as an infrastructure problem.

The company believes longevity care should begin with the individual rather than a standard menu of products or protocols. That means considering the patient's circumstances, available information, and clinical needs before discussing a potential approach.

This philosophy is consistent with Kaufman's broader vision for wellness. Rather than asking only what product a person should take, she wants the industry to ask what information can help practitioners make more informed decisions.

“I don't want Renuology to be known as another peptide or supplement company,” she says. “I want us to be known as a company that helped change the conversation from ‘What should I take?’ to ‘What does my body actually need?’”

Nearly 30 Years Of Experience Behind The Mission

Kaufman's path to Renuology spans multiple areas of the health and wellness industry. Her professional experience includes clinical practice, entrepreneurship, product formulation, and business leadership.

She co-founded and successfully exited an e-commerce company during the early dot com era. She also held leadership roles with Global Wellness Brands and has formulated more than 150 nutritional products. Her work includes four product patents.

That experience has given Kaufman exposure to the different stages of health and wellness innovation, from product development to business operations and consumer needs.

Her interest in personalized care is also shaped by personal loss. After losing her brother to Type 1 Diabetes, Kaufman's perspective on health changed. The experience strengthened her belief that people deserve better information about their bodies and access to practitioners who can help them make informed decisions.

That belief became part of the foundation of Renuology.

Today, she is applying her experience to a company focused on the intersection of genetics, precision wellness, peptide science, and clinical education.

Peptide DNA Testing Adds Another Layer Of Information

One of Renuology's initiatives is its Peptide DNA testing platform, designed to provide healthcare practitioners with additional genetic insights that may help inform individualized wellness strategies and peptide conversations.

The platform reflects the company's belief that personalized care should begin with understanding the individual. By exploring genetic information, practitioners may have another source of context to consider alongside patient history, clinical judgment, and other relevant information.

Genetic testing, however, does not independently determine a person's medical needs or guarantee how an individual will respond to a peptide. Its value depends on appropriate interpretation and how the information is used within clinical decision making.

Renuology's approach places the practitioner at the center of that process.

The company is also expanding its DNA platform into areas including methylation, metabolic health, nutrition, performance, hormones, brain health, and overall wellness. These areas reflect its interest in a broader understanding of the individual rather than a single product focused solution.

For practices exploring longevity medicine, the company's goal is to provide information that can contribute to more thoughtful conversations.

PeptideRx.Health Brings Clinical Tools Into One Ecosystem

Testing is one part of Renuology's infrastructure strategy. Another is PeptideRx.Health, the company's platform designed to bring dosing tools, protocol organization, science, education, and training into one ecosystem.

The platform addresses a practical issue facing practices: the need to manage multiple sources of information while building a more organized approach to peptide related care.

Rather than treating education, protocol resources, and scientific information as separate activities, Renuology is working to connect them through a single platform.

PeptideRx.Health is intended to support clinicians as they navigate the information surrounding peptide medicine. Its focus on dosing tools and protocol organization reflects the importance of practical resources, while its science, education, and training components speak to the need for continued professional learning.

The platform does not replace clinical judgment or establish that a particular peptide, dose, or protocol is appropriate for every patient. Instead, Renuology positions it as part of the supporting infrastructure that practices can use alongside appropriate medical oversight.

This distinction is central to the company's identity.

Medical Oversight And Education Before Hype

Renuology's approach to peptide access is built around practitioner involvement. The company says it works with healthcare practitioners rather than encouraging consumers to independently select peptide products.

It also states that its peptides undergo rigorous testing and are sourced through a quality focused process. These are company stated commitments and should not be interpreted as proof that every product is FDA approved or that every peptide has established clinical benefits.

For a field experiencing growing attention, the distinction between scientific interest, product availability, and proven medical application is important.

Kaufman believes responsible growth requires stronger education, medical oversight, and clear boundaries.

“Peptides are incredibly exciting, but the future isn't simply about having access to more therapies,” she says. “It's about becoming smarter and more precise about how we approach the individual.”

That perspective places limits on the idea that peptide medicine is simply a matter of offering more options. For Renuology, the larger question is how practices can develop the knowledge and systems needed to approach those options responsibly.

Building A More Complete Wellness Infrastructure

Renuology's leadership team brings more than 100 years of combined experience across clinical medicine, pharmaceutical development, formulation, and health innovation, according to company-provided information. This diverse expertise supports the company's goal of connecting multiple aspects of the wellness journey.

Kaufman's background as a clinician, entrepreneur, product formulator, and business leader gives her a broad perspective on industry challenges. Her personal experience with chronic disease also shapes the company's mission.

Rather than creating another supplement or peptide brand, Kaufman aims to help advance a more personalized approach to wellness.

“For decades, wellness has asked people to fit into protocols,” Kaufman says. “I believe the next generation of wellness will build protocols around the person.”

That vision spans DNA testing, peptide education, practitioner tools, and clinical infrastructure.

Recognition For Peptide Innovation

Renuology’s approach has also received recognition from Evergreen Awards, which named the company the Best Peptide Innovation Company in Juno Beach, Florida of 2026. The recognition highlights Renuology’s focus on personalization, practitioner education, genetic insights, peptide science, testing, and a person-first approach to wellness. Led by CEO and Co-Founder Ashlee Kaufman, PA-C, MMS, the company was recognized for its precision wellness approach. The award reflects Renuology’s philosophy and innovation, rather than an independent assessment of any peptide, product, protocol, safety, or clinical effectiveness.

Explore Renuology's Approach To Personalized Peptide Care

For medical practices and healthcare professionals exploring the evolving role of peptides in longevity care, Renuology offers insight into its approach at renuology.com.

Its PeptideRx.Health platform provides resources focused on dosing tools, protocol organization, science, education, and training. Readers can also follow Renuology on Instagram, Facebook, and LinkedIn to learn more about its developments.

Renuology aims to help practices navigate longevity medicine through stronger infrastructure, practitioner education, and individualized approaches to care. As interest in peptide medicine grows, the company emphasizes that meaningful progress involves more than access, it also requires reliable systems, information, and professional oversight to support informed decisions.

About Renuology

Renuology is a precision wellness company combining DNA insights, evidence-based peptides, clinical research, practitioner education, and PeptideRx.Health. The company is led by CEO and Co-Founder Ashlee Kaufman, PA-C, MMS.

Disclaimer: This article is for informational purposes only and does not constitute medical advice or endorse peptide medicine, genetic testing, or personalized healthcare. Consult a qualified healthcare professional before making medical decisions or pursuing these services. The author and publisher assume no responsibility for any losses, damages, or outcomes resulting from reliance on this information.